CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.

Cereblon (CRBN), a substrate receptor of the Cullin 4 RING E3 ubiquitin ligase complex, is the target of the immunomodulatory drugs lenalidomide and pomalidomide. Recently, it was demonstrated that binding of these drugs to CRBN promotes the ubiquitination and subsequent degradation of 2 common substrates, transcription factors Aiolos and Ikaros. Here we report that CC-122, a new chemical entity termed pleiotropic pathway modifier, binds CRBN and promotes degradation of Aiolos and Ikaros in diffuse large B-cell lymphoma (DLBCL) and T cells in vitro, in vivo, and in patients, resulting in both cell autonomous as well as immunostimulatory effects. In DLBCL cell lines, CC-122-induced degradation or short hairpin RNA-mediated knockdown of Aiolos and Ikaros correlates with increased transcription of interferon (IFN)-stimulated genes independent of IFN-α, -β, and -γ production and/or secretion and results in apoptosis in both activated B-cell (ABC) and germinal center B-cell DLBCL cell lines. Our results provide mechanistic insight into the cell-of-origin independent antilymphoma activity of CC-122, in contrast to the ABC subtype selective activity of lenalidomide.

[1]  L. Staudt,et al.  A Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator’s Choice in Relapsed/Refractory DLBCL , 2014 .

[2]  C. Fontanillo,et al.  IMiDs® Immunomodulatory Agents Regulate Interferon-Stimulated Genes through Cereblon-Mediated Aiolos Destruction in Multiple Myeloma (MM) Cells: Identification of a Novel Mechanism of Action and Pathway for Resistance , 2014 .

[3]  A. Santoro,et al.  CC-122 Degrades the Lymphoid Transcription Factor Aiolos (IKZF3) By Modulating Cereblon and Shows Clinical Activity in a Phase Ib Study of Subjects with Relapsed or Refractory Non-Hodgkin’s Lymphoma and Multiple Myeloma , 2014 .

[4]  T. Witzig,et al.  Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  H. Handa,et al.  Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs , 2014, Nature Structural &Molecular Biology.

[6]  W. Chan,et al.  MYC and BCL2 protein expression predicts survival in patients with diffuse large B‐cell lymphoma treated with rituximab , 2014, British journal of haematology.

[7]  Kai Fu,et al.  Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. , 2014, Blood.

[8]  S. Carr,et al.  Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells , 2014, Science.

[9]  Christopher J. Ott,et al.  The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins , 2014, Science.

[10]  H. Handa,et al.  Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN , 2013, British journal of haematology.

[11]  R. Chopra,et al.  A First In Human Dose Escalation Study Of CC-122, A First-In-Class Pleiotropic Pathway Modulator™ (PPM) Compound In Subjects With Relapsed Or Refractory Solid Tumors, Multiple Myeloma and Non-Hodgkin’s Lymphoma , 2013 .

[12]  J. Kuruvilla,et al.  Relapsed and refractory aggressive NHL: time for a change. , 2013, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[13]  R. Chopra,et al.  Lenalidomide efficacy in activated B‐cell‐like subtype diffuse large B‐cell lymphoma is dependent upon IRF4 and cereblon expression , 2012, British journal of haematology.

[14]  C. Montagna,et al.  Silencing of the Il2 gene transcription is regulated by epigenetic changes in anergic T cells , 2012, European journal of immunology.

[15]  J. Seavitt,et al.  Aiolos promotes TH17 differentiation by directly silencing Il2 expression , 2012, Nature Immunology.

[16]  Paul Shinn,et al.  Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. , 2012, Cancer cell.

[17]  J. Seavitt,et al.  Harnessing of the Nucleosome Remodeling Deacetylase complex controls lymphocyte development and prevents leukemogenesis , 2011, Nature Immunology.

[18]  A. Rosenwald,et al.  The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Vose,et al.  An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  S. Barrans,et al.  Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Mandal,et al.  Ikaros and Aiolos Inhibit Pre-B-Cell Proliferation by Directly Suppressing c-Myc Expression , 2010, Molecular and Cellular Biology.

[22]  J. Blenis,et al.  ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. , 2010, Molecular cell.

[23]  Wenjing Zhang,et al.  Identification of XAF1 as a novel cell cycle regulator through modulating G(2)/M checkpoint and interaction with checkpoint kinase 1 in gastrointestinal cancer. , 2009, Carcinogenesis.

[24]  Jiangwen Zhang,et al.  Genome-wide lineage-specific transcriptional networks underscore Ikaros-dependent lymphoid priming in hematopoietic stem cells. , 2009, Immunity.

[25]  L. Staudt,et al.  Stromal gene signatures in large-B-cell lymphomas. , 2008, The New England journal of medicine.

[26]  I. Lossos,et al.  Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  D. Leaman,et al.  Mitochondrial localization and pro-apoptotic effects of the interferon-inducible protein ISG12a , 2008, Apoptosis.

[28]  S. Ng,et al.  Early hematopoietic lineage restrictions directed by Ikaros , 2006, Nature Immunology.

[29]  P. Gaulard,et al.  Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  L. Staudt,et al.  Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. , 2004, Blood.

[31]  K. Georgopoulos,et al.  Ikaros-CtIP Interactions Do Not Require C-terminal Binding Protein and Participate in a Deacetylase-independent Mode of Repression* , 2002, The Journal of Biological Chemistry.

[32]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[33]  D. Weisenburger,et al.  New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  D. Longo,et al.  Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. , 1984, The New England journal of medicine.

[35]  N. Berinstein,et al.  Alterations of the p53 tumor suppressor gene in diffuse large cell lymphomas with translocations of the c-MYC and BCL-2 proto-oncogenes. , 1994, Blood.

[36]  Supplementary Methods , 2022 .